Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Sirius XM Holdings Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Sirius XM Holdings Inc trades at $30.46 (market cap $10.23B). The key difference: Sirius XM Holdings Inc is the larger of the two by market cap, and Sirius XM Holdings Inc pays a 3.55% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | SIRI | |
|---|---|---|
Market Cap | $8.04B | $10.23B |
Sector | Health | Media |
52-Week High | $339.75 | $30.75 |
52-Week Low | $241.71 | $19.92 |
Enterprise Value | $7.85B | $19.90B |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Sirius XM Holdings (SIRI) trades at $30.67, up 0.82% with strong technical momentum and bullish moving average signals. The company shows improved fundamentals with three consecutive quarterly earnings beats and a return to profitability in 2025 after a challenging 2024. Recent developments include a strategic advertising partnership with YouTube and potential merger discussions with iHeartMedia, driving positive investor sentiment.
The outlook remains positive with analysts maintaining a $31.17 consensus target and 58% buy ratings. Key opportunities include revenue diversification through new partnerships and strong cash flow generation supporting dividends and buybacks. Risks include intense media competition and high debt levels despite recent improvement from 94% to 36% debt-to-asset ratio since 2022.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
